Table 1.
Demographic and metabolic characteristics of study subjects.
| Characteristic | Non-NAFLD (N = 49) | NAFLD (N = 49) | p |
|---|---|---|---|
| General | |||
| Gender, n (%) | 0.832 | ||
| Male | 33 (67.3%) | 31 (63.3%) | |
| Female | 16 (32.7%) | 18 (36.7%) | |
| Age, year | 57.22 ± 12.33 | 58.88 ± 12.89 | 0.431 |
| Duration of diabetes, year | 9 (4, 15) | 6 (0, 10) | 0.042 |
| BMI, kg/m2 | 26.12 (25.08, 28.3) | 28.76 (26.93, 30.9) | <0.001 |
|
| |||
| Biochemical markers | |||
| FBG, mmol/L | 7.66 (6.38, 9.85) | 9.99 (7.49, 12.88) | 0.017 |
| HbA1c, % | 8 (6.8, 10.4) | 10 (8.57, 11.4) | <0.001 |
| LDL, mmol/L | 2.25 ± 0.74 | 2.68 ± 0.87 | 0.012 |
| HDL, mmol/L | 0.96 (0.81, 1.1) | 0.84 (0.72, 0.98) | 0.009 |
| ALT, IU/L | 22 (17, 39) | 25 (18, 42) | 0.384 |
| AST, IU/L | 23 (17, 29) | 21 (15, 33) | 0.440 |
| eGFR, ml/min/1.73 m2 | 115.23 ± 51.74 | 121.59 ± 45.18 | 0.154 |
| FT3, pmol/L | 5.03 (4.52, 5.34) | 4.76 (4.34, 5.28) | 0.238 |
| FT4, pmol/L | 13.03 (11.33, 13.79) | 14.17 (12.49, 16.07) | 0.005 |
| TSH, mIU/L | 1.26 (0.9, 1.71) | 1.94 (1.12, 2.95) | 0.004 |
|
| |||
| Use of hypoglycemic drugs | |||
| Insulin (N, %) | 20 (40.8%) | 21 (42.9%) | 0.838 |
| Metformin (N, %) | 28 (57.1%) | 29 (59.2%) | 0.838 |
| Thiazolidinediones (N, %) | 2 (4.1%) | 3 (6.1%) | 0.646 |
| Sulfonylureas/glinides (N, %) | 3 (6.1%) | 3 (6.1%) | 1.000 |
| Glucosidase inhibitors | 11 (22.4%) | 11 (22.4%) | 1.000 |
| SGLT2 inhibitors | 21 (42.9%) | 29 (59.2%) | 0.106 |